Table 1.
Demographic and treatment characteristics
| Cases (n=13) | Controls (n=14) | |
|---|---|---|
| Mean (SD) | Mean (SD) | |
| Age at baseline (years) | 47.76 (6.4) | 48.21 (7.7) |
| Education (years) | 17 (6.4) | 16 (7.8) |
| N (%) | N (%) | |
| Race & ethnicity | ||
| Caucasian | 5 (38) | 12 (85) |
| African-American | 1 (7) | 2 (14) |
| Asian | 5 (38) | 0 (0) |
| Hispanic | 2 (15) | 0 (0) |
| Handedness | ||
| Right | 13 (100) | 14 (100) |
| Left | 0 (0) | 0 (0) |
| Menopausal Status (baseline) | ||
| Pre | 6 (46) | 5 (35) |
| Peri | 2 (15) | 3 (21) |
| Post | 5 (38) | 6 (43) |
| Time from surgery to baseline scan | 46 (17) | |
| Cancer stage | ||
| i | 3 (21) | |
| ii | 1 (7) | |
| iia | 4 (28) | |
| iib | 1 (7) | |
| iiia | 2 (14) | |
| No stage recorded | 2 (14) | |
| Chemotherapy type | ||
| Adriamycin, Cytoxan, and Taxol | 9 (69) | |
| Cyclophosphamide, methotrexate, fluorouracil | 4 (28) | |
| Hormone Therapy | 10 (78) | |
| Tamoxifen | 1 (10) | |
| Arimedex | 8 (80) | |
| Femara | 1 (10) | |
| Radiation Therapy | 12 (92) | |
| Mean (range) | Mean (range) | |
| STAI-S | ||
| Baseline | 31 (21-46) | 27 (21-47) |
| Followup | 30 (20-50) | 33 (22-68) |
| CES-D | ||
| Baseline | 10 (2-20) | 6 (0-20) |
| Followup | 8 (2-14) | 9 (1-29) |
Note. No differences were found for age or education or handedness between cases and controls